Elicera Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELIC.ST research report →
Companywww.elicera.com
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer.
- CEO
- Jamal El-Mosleh
- IPO
- 2021
- Employees
- 2
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $149.69M
- P/E
- -10.09
- P/S
- 55.52
- P/B
- 7.97
- EV/EBITDA
- -8.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -556.04%
- Net Margin
- -536.06%
- ROE
- -56.67%
- ROIC
- -81.92%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-17,406,665 · -8.05%
- EPS
- $-0.38 · 25.49%
- Op Income
- $-17,944,682
- FCF YoY
- 8.15%
Performance & Tape
- 52W High
- $8.43
- 52W Low
- $2.93
- 50D MA
- $4.46
- 200D MA
- $5.54
- Beta
- 0.30
- Avg Volume
- 205.98K
Get TickerSpark's AI analysis on ELIC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ELIC.ST Coverage
We haven't published any research on ELIC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELIC.ST Report →